NRIX ▼ -35.0% - Nurix Therapeutics, Inc. $NRIX Nurix Therapeutics: Sanofi Discontinues Phase 1 Trial of STAT6 Degrader SAR448272, Terminates Development Program ? • Discontinuation: Sanofi ends the Phase 1 trial and terminates the SAR448272 development program. • Financial Impact: Nurix no longer expects future milestone payments or royalties from SAR448272. • Cash Runway: Unchanged, with $1.1B in cash and investments expected to fund operations into H2 2029. • Pipeline: Roche-partnered bexobrutideg remains in Phase 3, while NX-1607 and Gilead-partnered GS-6791 continue clinical development. 03-NOV-2026 04:07 PM ET